首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1575720

全球輸液治療市場 - 2024-2031

Global Infusion Therapy Market - 2024-2031

出版日期: 2024年10月22日 | 出版商:

DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

全球輸液治療市場在 2023 年達到 435 億美元，預計到 2031 年將達到 737 億美元，2024-2031 年預測期間複合年成長率為 6.8%。

輸液療法也稱為靜脈注射 (IV) 療法，是一種涉及透過針或導管將藥物、液體或營養物質直接輸送到患者血液中的醫療程序。此方法主要用於為各種醫療狀況提供即時有效的治療。

輸注療法是比口服藥物更安全的替代方案，特別是對於吞嚥困難的患者。在胃酸可能會損害某些藥物的有效性、降低其療效的情況下，它也很有用。輸液治療對於管理需要精確劑量和不間斷給藥的醫療狀況至關重要。持續、準確地輸送藥物的能力對於有效治療各種健康問題至關重要。

市場動態：

司機

慢性病盛行率上升和技術進步

全球輸液治療市場的需求是由多種因素所驅動的。主要因素之一是慢性病盛行率上升和技術進步。糖尿病、癌症和心血管疾病等慢性病發病率的上升極大地推動了輸液治療市場的發展。這些疾病通常需要長期管理和精確的藥物輸送，這使得輸液療法變得越來越重要。

根據世界衛生組織（WHO）2024年的資料，心血管疾病是全球主要死亡原因，每年約導致1,790萬人死亡。輸液治療在治療心臟衰竭等疾病方面發揮著至關重要的作用，持續的藥物傳遞對於實現最佳患者治療效果至關重要。

輸液設備的創新，特別是與電子健康記錄 (EHR) 整合以進行即時監控的智慧型輸液幫浦的開發，正在顯著提高患者的安全和治療效果。這些進步正在改變輸液治療的格局，使其更有效率且方便用戶使用，這將推動市場成長。

此外，該行業技術進步的關鍵參與者（例如引入慢性病創新療法和推出先進軟體）推動了該市場的成長。例如，2024 年 2 月，NHS 推出了一種治療晚期帕金森氏症的新療法，稱為 foslevodopa-foscarbidopa，也稱為 Produodopa。這種創新療法專為傳統口服藥物無法充分控制症狀的患者而設計。它涉及一個攜帶式、穿戴式的輸液系統，透過佩戴在皮下的小泵持續輸送藥物，從而實現 24 小時症狀管理。

同樣，2023 年 6 月，B. Braun Medical Inc. 推出了最新的輸液管理軟體 DoseTrac Enterprise Infusion Management Software，旨在加強醫療機構內輸液幫浦的管理。這種先進的軟體提供了即時監控和回顧性報告功能的組合，使組織能夠更深入地了解其輸液幫浦組和相關資料。

限制

先進技術的高成本、設備的風險和複雜性以及監管和報銷挑戰等因素預計將阻礙市場的發展。

細分市場分析

全球輸液治療市場根據產品類型、給藥途徑、應用、最終用戶和地區進行細分。

輸液幫浦領域約佔全球輸液治療市佔率的52.1%

預計輸液幫浦領域在預測期內將佔據最大的市場佔有率。對準確、高效的藥物輸送系統的需求不斷成長，導致輸液泵的使用增加。這些設備專門設計用於以規定劑量向患者輸送液體、藥物或營養物質，這使得它們對於廣泛的醫療應用至關重要。

輸液幫浦領域的特點是不斷的技術進步，顯著提高了病患的安全和治療效果。最引人注目的創新之一是智慧型輸液幫浦的開發，它與電子健康記錄 (EHR) 無縫整合，以方便即時監控患者資料。

整合電子健康記錄 (EHR) 的智慧輸液幫浦可最大限度地降低用藥錯誤的風險，從而顯著提高病患安全。該技術允許將藥物訂單直接從 EHR 自動傳輸到輸液泵，無需手動編程並減少人為錯誤的可能性。

此外，行業主要參與者的產品發布和輸液泵的關鍵發展正在推動該細分市場的成長。例如，2023年2月，邁瑞推出了BeneFusion i系列和u系列輸液系統，標誌著輸液技術的重大進步，強調高精度、自適應客製化和方便用戶使用的介面，以提高各種臨床環境中的用藥安全性。這項發展符合採用智慧輸液幫浦的日益成長的趨勢，智慧輸液幫浦已從基本的機械設備發展到旨在最大限度地減少用藥錯誤並改善患者治療效果的複雜系統。

同樣，2023 年 4 月，Eitan Medical 推出了 Avoset 輸液系統，這是一種尖端的連接動態輸液泵，旨在增強急性後護理和專業輸液治療。該創新系統致力於透過其緊湊的設計和先進的技術來提高患者安全和用戶體驗。

市場地理分析

北美約佔全球輸液治療市佔率的44.6%

由於癌症、糖尿病和心血管疾病等慢性疾病發病率的增加，顯著推動了北美對輸液治療的需求，預計北美地區將在預測期內佔據最大的市場佔有率。

據美國癌症協會稱，2021年美國新診斷出約190萬癌症病例。的需求增加。

同樣，美國醫院協會表示，美國約有 1.33 億人（近一半人口）患有至少一種慢性病，如高血壓、心臟病或關節炎。到 2030 年，這一數字預計將增至約 1.7 億，凸顯慢性病對該國醫療保健系統帶來的負擔日益加重。

此外，在該地區，大量關鍵參與者的存在、先進的醫療基礎設施、技術進步、政府優惠的報銷政策、對家庭醫療服務、產品發布和核准不斷成長的需求將推動該市場的成長。

例如，2024 年 4 月，Mackenzie Health 在加拿大推出了 BD Alaris EMR 互通性系統，代表了靜脈 (IV) 藥物管理的重大進步。這項創新技術可實現靜脈輸液幫浦與病患電子病歷 (EMR) 之間的雙向通訊，從而簡化輸液流程並提高病患安全。

此外，2024 年 4 月，Baxter International Inc. 的配備 Dose IQ 安全軟體的 Novum IQ 大容量輸液幫浦 (LVP) 獲得了 FDA 510(k) 許可。 Novum IQ 輸液平台已包含注射器輸液幫浦 (SYR)，這項新增功能使醫療保健提供者能夠在各種病患照護環境中使用統一的系統。 Novum IQ 平台透過整合 LVP 和 SYR 幫浦增強了使用者體驗，從而減輕了臨床醫生非關鍵任務的工作量。這種整合有助於簡化培訓過程，並減少與管理多個泵浦系統相關的認知負擔。

Infusion therapy, also known as intravenous (IV) therapy, is a medical procedure that involves delivering medications, fluids, or nutrients directly into a patient's bloodstream through a needle or catheter. This method is primarily used to provide immediate and effective treatment for various medical conditions.

Infusion therapy serves as a safer alternative to oral medication, particularly for patients who have difficulty swallowing. It is also beneficial in situations where stomach acids could compromise the effectiveness of certain medications, rendering them less effective. Infusion therapy is crucial for managing medical conditions that necessitate precise dosing and uninterrupted medication administration. The ability to deliver medications continuously and accurately is vital for effectively treating various health issues.

Market Dynamics: Drivers

Rising prevalence of chronic diseases and technological advancements

The demand for the global infusion therapy market is driven by multiple factors. One of the primary factors is the rising prevalence of chronic diseases and technological advancements. The rising incidence of chronic conditions such as diabetes, cancer, and cardiovascular diseases significantly drives the infusion therapy market. These diseases often require long-term management and precise medication delivery, which makes infusion therapies increasingly essential.

According to the World Health Organization (WHO) data in 2024, indicates that cardiovascular diseases are the leading cause of death worldwide, responsible for approximately 17.9 million fatalities each year. Infusion therapy plays a vital role in managing conditions like heart failure, where continuous medication delivery is essential for achieving optimal patient outcomes.

Innovations in infusion devices, particularly the development of smart infusion pumps that integrate with electronic health records (EHRs) for real-time monitoring, are significantly enhancing patient safety and treatment efficacy. These advancements are transforming the landscape of infusion therapy, making it more efficient and user-friendly, which would propel market growth.

Moreover, key players in the industry's technological advancements such as the introduction of innovative treatments for chronic diseases and launching advanced software propel this market growth. For instance, in February 2024, the NHS launched a new treatment for advanced Parkinson's disease known as foslevodopa-foscarbidopa, also referred to as Produodopa. This innovative therapy is designed for patients whose symptoms are not adequately managed by traditional oral medications. It involves a portable, wearable infusion system that continuously delivers medication through a small pump worn under the skin, allowing for 24-hour symptom management.

Similarly, in June 2023, B. Braun Medical Inc. unveiled its latest infusion management software, DoseTrac Enterprise Infusion Management Software, aimed at enhancing the management of infusion pumps within healthcare organizations. This advanced software provides a combination of real-time monitoring and retrospective reporting capabilities, allowing organizations to gain deeper insights into their infusion pump fleet and the associated data.

Restraints

Factors such as the high cost of advanced technologies, risk & complexity of devices, and regulatory & reimbursement challenges are expected to hamper the market.

Market Segment Analysis

The global infusion therapy market is segmented based on product type, route of administration, application, end-user, and region.

The infusion pumps segment accounted for approximately 52.1% of the global infusion therapy market share

The infusion pumps segment is expected to hold the largest market share over the forecast period. The growing need for accurate and efficient medication delivery systems has led to a rise in the use of infusion pumps. These devices are specifically designed to administer fluids, medications, or nutrients to patients in regulated doses, making them crucial for a wide range of medical applications.

The infusion pumps segment is marked by ongoing technological advancements that significantly enhance patient safety and treatment effectiveness. One of the most notable innovations is the development of smart infusion pumps, which integrate seamlessly with electronic health records (EHRs) to facilitate real-time monitoring of patient data.

Smart infusion pumps with electronic health record (EHR) integration offer a significant improvement in patient safety by minimizing the risk of medication administration errors. This technology allows for the automatic transmission of medication orders directly from the EHR to the infusion pump, eliminating the need for manual programming and reducing the potential for human error.

Moreover, key players in the industry product launches and key developments in the infusion pumps are driving this segment growth in the market. For instance, in February 2023, Mindray launched the BeneFusion i Series and u Series infusion systems marking a significant advancement in infusion technology, emphasizing high precision, adaptive customization, and user-friendly interfaces to enhance medication safety across various clinical settings. This development aligns with the growing trend of adopting smart infusion pumps, which have evolved from basic mechanical devices to sophisticated systems designed to minimize medication errors and improve patient outcomes.

Similarly, in April 2023, Eitan Medical introduced the Avoset Infusion System, a cutting-edge connected ambulatory infusion pump designed to enhance post-acute care and specialty infusion therapy. This innovative system focuses on improving patient safety and user experience through its compact design and advanced technology.

Market Geographical Analysis

North America accounted for approximately 44.6% of the global infusion therapy market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing incidence of chronic diseases such as cancer, diabetes, and cardiovascular conditions significantly driving the demand for infusion therapy in North America.

According to the American Cancer Society, around 1.9 million new cancer cases were diagnosed in the United States in 2021. Many individuals diagnosed with cancer require infusion therapy for treatments such as chemotherapy and other supportive care, which leads to an increased demand for related products and services.

Similarly, American Hospital Association, stated that around 133 million people in the United States, which is nearly half the population, suffer from at least one chronic condition, such as hypertension, heart disease, or arthritis. This number is expected to rise to approximately 170 million by the year 2030, underscoring the increasing burden that chronic diseases place on the healthcare system in the country.

Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, technological advancements, government favorable reimbursement policies, growing demand for home healthcare services, product launches, and approvals would drive this market growth.

For instance, in April 2024, in Canada, Mackenzie Health's launch of the BD Alaris EMR Interoperability system represents a significant advancement in intravenous (IV) medication management. This innovative technology enables two-way communication between IV infusion pumps and the patient's electronic medical record (EMR), streamlining the infusion process and enhancing patient safety.

Also, in April 2024, Baxter International Inc. received FDA 510(k) clearance for its Novum IQ large volume infusion pump (LVP) equipped with Dose IQ Safety Software. This addition to the Novum IQ Infusion Platform, which already includes a syringe infusion pump (SYR), allows healthcare providers to utilize a unified system across various patient care environments. The Novum IQ platform enhances the user experience by integrating the LVP and SYR pumps, thereby alleviating the workload of non-critical tasks for clinicians. This integration facilitates a streamlined training process and reduces the cognitive load associated with managing multiple pump systems.

Market Segmentation

By Product Type

Infusion Pumps

Intravenous Sets

IV Cannulas

Needleless Connectors

Vein Imaging Devices

By Route of Administration

Intramuscular

Subcutaneous

Epidural

By Application

Antibiotic & Viral

Inotropic Therapy

Anti-coagulation

Chemotherapy

Nutritional Therapy

Blood Component

Others

By End-User

Hospitals & Specialty Clinics

Ambulatory Surgery Centers

Homecare Settings

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

The rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the infusion therapy market include B. Braun Melsungen AG, ICU Medical, Inc., Baxter International Inc., Fresenius Kabi AG, Terumo Corporation, Becton, Dickinson and Company, Nipro Corporation, Mindray Medical India Pvt. Ltd., Moog Inc., and Teleflex Incorporated among others.

Key Developments

In January 2024, AbbVie launched Produodopa (foslevodopa/foscarbidopa), a continuous subcutaneous infusion therapy, for the treatment of advanced Parkinson's disease in the European Union. Produodopa is the first and only 24-hour levodopa-based subcutaneous infusion therapy approved for this indication in the EU.

In June 2023, Eitan Medical introduced Eitan Insights, a new cloud-based infusion management system tailored for home and specialty infusion needs. This innovative platform connects with Eitan Medical's infusion systems, including the Sapphire pump, which now features a universal plug-and-play cellular accessory called Sapphire Connect, and the Avoset pump, complemented by the AvosetGo app.

Why Purchase the Report?

To visualize the global infusion therapy market segmentation based on product type, route of administration, application, end-user, and region and understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the infusion therapy market with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global infusion therapy market report would provide approximately 70 tables, 68 figures, and 183 pages

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Route of Administration
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Chronic Diseases and Technological Advancements
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of Advanced Technologies
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Infusion Pumps *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Intravenous Sets
6.4. IV Cannulas
6.5. Needleless Connectors
6.6. Vein Imaging Devices

7. By Route of Administration

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Intramuscular *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Subcutaneous
7.4. Epidural

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Antibiotic & Viral *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Inotropic Therapy
8.4. Anti-coagulation
8.5. Chemotherapy
8.6. Nutritional Therapy
8.7. Blood Component
8.8. Others

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals & Specialty Clinics *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgery Centers
9.4. Homecare Settings

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.9. Brazil
- 10.4.10. Argentina
- 10.4.11. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. B. Braun Melsungen AG*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. ICU Medical, Inc.
12.3. Baxter International Inc.
12.4. Fresenius Kabi AG
12.5. Terumo Corporation
12.6. Becton, Dickinson and Company
12.7. Nipro Corporation
12.8. Mindray Medical India Pvt. Ltd.
12.9. Moog Inc.
12.10. Teleflex Incorporated (*LIST NOT EXHAUSTIVE)